全球噬菌体疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

预计噬菌体疗法市场将从 2025 年的 12.7 亿美元成长到 2034 年的 18.4 亿美元，2026 年至 2034 年的复合年增长率为 4.17%。

全球噬菌体疗法市场正日益受到关注，被视为治疗细菌感染的替代方法。噬菌体疗法利用病毒特异性靶向并摧毁有害细菌，而不会影响有益微生物。这种治疗方法正被探索作为解决日益严重的全球健康问题——抗生素抗药性——的潜在方案。

多种因素共同推动了这一市场的成长。抗生素抗药性感染疾病的增加迫使研究人员探索新的治疗方法。噬菌体疗法提供了一种标靶治疗方案，与传统抗生素相比，可能降低抗药性产生的风险。此外，正在进行的研究和临床试验正在加深我们对噬菌体治疗潜力的理解。

随着人们对替代抗菌治疗方法的兴趣日益浓厚，噬菌体疗法市场前景一片光明。生物技术和基因研究的进步有望提高噬菌体疗法的疗效和安全性。随着医学界不断寻求应对抗生素抗药性的解决方案，噬菌体疗法有望成为重要的治疗选择。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球噬菌体疗法市场：以标靶细菌划分

• 市场分析、洞察与预测
• 大肠桿菌
• 金黄色葡萄球菌
• 链球菌
• 铜绿假单胞菌
• 沙门氏菌
• 其他的

第五章 全球噬菌体疗法市场：依适应症划分

• 市场分析、洞察与预测
• 尿道感染
• 慢性中耳炎
• 拔牙
• 慢性溃疡性大肠炎
• 骨感染疾病
• 伤口和皮肤感染疾病
• 囊肿纤维化
• 其他的

第六章 全球噬菌体疗法市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 局部行政部门
• 肠外

第七章 全球噬菌体疗法市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球噬菌体疗法市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Armata Pharmaceuticals Inc
  • Adaptive Phage Therapeutics Inc
  • BiomX Inc
  • Intralytix Inc
  • Locus Biosciences Inc
  • ContraFect Corporation
  • Micreos BV
  • Enbiotix Inc
  • PhagePro Inc
  • Phagomed Biopharma GmbH
  • Eligo Bioscience SA
  • Pherecydes Pharma
  • Nextbiotics
  • InnoPhage Ltd
  • Phi Therapeutics

The Bacteriophage Therapy Market size is expected to reach USD 1.84 Billion in 2034 from USD 1.27 Billion (2025) growing at a CAGR of 4.17% during 2026-2034.

The global bacteriophage therapy market is gaining attention as an alternative approach to treating bacterial infections. Bacteriophage therapy uses viruses that specifically target and destroy harmful bacteria without affecting beneficial microorganisms. This treatment method is being explored as a potential solution to antibiotic resistance, which has become a significant global health concern.

Several factors are contributing to the growth of this market. The rising prevalence of antibiotic-resistant infections is encouraging researchers to explore new treatment methods. Bacteriophage therapy offers a targeted approach that may reduce the risk of resistance compared to conventional antibiotics. Additionally, ongoing research and clinical trials are expanding knowledge about the therapeutic potential of bacteriophages.

The future outlook for the bacteriophage therapy market appears promising as interest in alternative antimicrobial treatments increases. Advances in biotechnology and genetic research are expected to improve the effectiveness and safety of bacteriophage therapies. As the medical community continues to search for solutions to antibiotic resistance, bacteriophage therapy may become an important treatment option.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Targeted Bacteria

• Escherichia coli
• Staphylococcus aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others

By Disease Indication

• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others

By Route of Administration

• Oral
• Topical
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Armata Pharmaceuticals Inc, Adaptive Phage Therapeutics Inc, BiomX Inc, Intralytix Inc, Locus Biosciences Inc, ContraFect Corporation, Micreos BV, Enbiotix Inc, PhagePro Inc, Phagomed Biopharma GmbH, Eligo Bioscience SA, Pherecydes Pharma, Nextbiotics, InnoPhage Ltd, Phi Therapeutics
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY TARGETED BACTERIA 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Targeted Bacteria
• 4.2. Escherichia coli Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Staphylococcus aureus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Streptococcus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Pseudomonas aeruginosa Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Salmonella Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Urinary Tract Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Chronic Otitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Dental Extraction Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Chronic Ulcerative Colitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Bone Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Wound and Skin Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Cystic Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Targeted Bacteria
  • 8.2.2 By Disease Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Targeted Bacteria
  • 8.3.2 By Disease Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Targeted Bacteria
  • 8.4.2 By Disease Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Targeted Bacteria
  • 8.5.2 By Disease Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Targeted Bacteria
  • 8.6.2 By Disease Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BACTERIOPHAGE THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Armata Pharmaceuticals Inc
  • 10.2.2 Adaptive Phage Therapeutics Inc
  • 10.2.3 BiomX Inc
  • 10.2.4 Intralytix Inc
  • 10.2.5 Locus Biosciences Inc
  • 10.2.6 ContraFect Corporation
  • 10.2.7 Micreos B.V
  • 10.2.8 Enbiotix Inc
  • 10.2.9 PhagePro Inc
  • 10.2.10 Phagomed Biopharma GmbH
  • 10.2.11 Eligo Bioscience SA
  • 10.2.12 Pherecydes Pharma
  • 10.2.13 Nextbiotics
  • 10.2.14 InnoPhage Ltd
  • 10.2.15 Phi Therapeutics